Exciting changes are coming! Jan. 1, 2026, we’ll be launching a brand-new website experience. Stay tuned! Learn More

Brexucabtagene autoleucel, up to 200 million autologous anti-CD19 CAR positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Powered by Lapero